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Abstract 
Background: Cases of transfusion‑transmitted malaria have been described around the world and highlighted in 
some studies. Semi‑immune individuals are more likely to transmit malaria as they may be asymptomatic. Some coun‑
tries allow blood donations only based on epidemiological criteria while others reinforce their criteria with serologi‑
cal tests. However, little is known about the longevity of anti‑Plasmodium spp. antibodies and its meaning in blood 
donation. Therefore, this study aims to assess the longevity of different subclasses of anti‑Plasmodium spp. antibodies 
in individuals with previous stays in endemic areas, as well as to assess how those antibodies are related to personal 
features and travel characteristics. Based on those results, the suitability of the Portuguese blood donors screening 
method was addressed, i.e. the method to search for an eventual risk of transfusion–transmitted malaria among the 
population studied.
Results: Statistical associations were found between the presence of total anti‑Plasmodium spp. antibodies and 
some travel characteristics, namely to be born in endemic area versus non endemic and previous episodes of malaria. 
The intersection between seropositive results and the last year of stay in endemic areas showed a longer longevity 
of anti‑Plasmodium spp. antibodies than previously reported. Those results represented a considerable portion of the 
individuals having returned from their last stay in endemic areas more than 10 years before enrolment in this study. 
Considering the study population as potential blood donors, serological results also indicated that if epidemiologi‑
cal criteria alone were applied to screen blood donors, an important percentage of seropositive individuals would be 
approved for blood donation. Because the nature and meaning of those antibodies in the blood donation context is 
still not understood, those approved individuals could represent a risk for blood transfusion safety.
Conclusions: The place of birth and past episodes of malaria seem to be related to the serological outcome. Epide‑
miological criteria to screen potential blood donors are insufficient to guarantee the safety of the blood, if applied 
alone.
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Background
Malaria is an infectious disease with five species of Plas-
modium infective to humans. Malaria is endemic in 
tropical and sub-tropical regions, being the sub-Saharan 
region the most affected, where Plasmodium falciparum 
is the most prevalent species [1].
Since a protective immune response against Plasmo-
dium infection is strain-specific, several infections are 
required in order to contact with a wide repertoire of 
Plasmodium antigens and fulfil the compartment of 
immunologic memory [2]. A protective immunity against 
the infection is rare or never achieved. However individ-
uals may become semi-immune to the disease, living in 
balance with the parasite and carrying it in their blood-
stream without symptoms [3].
Some studies have suggested that when individu-
als leave endemic areas for some period of time, semi-
immunity may be lost [4]. However, little is known 
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about antibody dynamics in the context of malaria and 
the period of time needed for seroreversion is not well 
determined. A study of Fowkes et al. which was based on 
a mathematical model, estimated antibodies half-life of 
7.6 years in a population of pregnant women [5]. Faddy 
et al. studied a population of blood donors and concluded 
that antibodies anti-Plasmodium spp. may persist in the 
bloodstream up to 19.6  months after the last exposure 
[6]. In addition, the majority of the research work pub-
lished cannot be analysed in the context of the longev-
ity of anti-Plasmodium spp. antibodies: (a) many studies 
focus on children populations, whose immune system is 
still in development and thus, it may not be appropriate 
to extrapolate conclusions to adult populations [7, 8]; (b) 
some studies were performed in endemic areas where 
people are constantly at risk of being infected [8, 9] and 
thus, data about the last exposure and antibody longevity 
may not be accurate; (c) some studies focus mainly on the 
existence of parasitaemia at the time of blood collection 
[10, 11], and (d) some studies only focus on a small num-
ber of parasite proteins that generate a humoral response 
in vaccine studies [12]. Therefore, to better understand 
the longevity of malaria antibodies or which features 
may influence it, a study was conducted in a naturally-
exposed adult population that is no longer exposed to the 
parasite. Since semi-immune individuals may live in bal-
ance with the parasite without symptoms, these people 
are more likely to transmit infection through blood trans-
fusion [3, 13].
Transfusion-transmitted malaria has been reported 
globally, involving children and adults [14–20]. In 
order to avoid that problem, several governments and 
other organizations, including the Council of Europe 
or World Health Organization, created a set of poli-
cies and recommendations establishing conditions that 
shall be applied to potential blood donors [21–23]. 
In endemic countries, where people are commonly 
semi-immune, the parasite loads may be undetect-
able with the available detection techniques. Therefore, 
transfusion strategies focus on chemoprophylaxis for 
the donor and recipient, or ensure that the blood col-
lected in areas of high endemicity is not transfused to 
recipients of low endemicity areas [24]. Despite the 
efforts, donations frequently end up with the infec-
tion of the recipient [20, 25–28]. On the other hand, 
in nonendemic countries, the strategy to minimize 
the risk of transmitting malaria through blood trans-
fusion is based on the probability of an individual to 
transmit the parasite at the moment of blood donation. 
Therefore, some countries only apply selective epide-
miological questionnaires (e.g. Canada, USA) [29–31], 
while others reinforce their selection measures with 
immunological tests and/or molecular techniques (e.g. 
Australia, France, England, Italy, Spain and Portugal 
[21, 32–36]. The Portuguese Institute for Blood and 
Transplantation bases its procedures on a Portuguese 
statement that regulates blood donations for individu-
als with stays in malaria-endemic areas, who wish to 
donate blood [21–23, 37]; Table 1 summarizes the Por-
tuguese criteria for donors approval.
The historical and cultural proximity between Portugal 
and some endemic countries, such as Angola, Guinea-
Bissau, São Tomé and Príncipe, Mozambique, and Brazil, 
makes Portugal at risk of receiving semi-immune peo-
ple that later may donate blood [38]. Besides, there are 
no estimates about the prevalence of individuals with 
anti-Plasmodium spp. antibodies in Portugal. Thus, the 
present work aims to better understand the dynam-
ics of anti-Plasmodium spp. antibodies in a popula-
tion of adults, naturally-exposed to Plasmodium spp. at 
some moment of their lives. Specifically, this study aims 
to determine the longevity of anti-Plasmodium spp. 
antibodies; how that longevity may be related to demo-
graphic characteristics and travel features; and, according 
to that, a question about the suitability of the screening 
method of blood donors was raised, regarding the sub-
stantial need of blood units versus the potential risk of 
transmitting malaria.
Table 1 Criteria for donor blood screening, according to the Portuguese Institute for Blood and Transplantation
Risk category Guidelines
Individuals who lived the first 5 years of life in endemic areas Approved 3 years after the last stay in endemic areas, since asymptomatic 
or approved 4 months after return if serological or molecular tests are 
negative
Previous episodes of malaria Approved 3 years after cessation of last symptoms/treatment and only if 
serological or molecular tests are negative
Asymptomatic visitors (stays < 6 months) Approved 1 year after returning of endemic areas or approved if serological 
or molecular tests are negative
Febrile episodes undiagnosed during or 6 months after a travel to 
endemic areas
Approved 3 years after returning from endemic areas and cessation of 
symptoms or approved 4 months after return if serological or molecular 
tests are negative
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Methods
Study population
The population studied included 505 individuals that ful-
fil the following criteria: (1) age between 18 and 65 years 
old; (2) have stayed in endemic areas of malaria, indepen-
dently of having a history of malaria episodes, length of 
stay or reason for travelling.
All individuals that attended different phlebotomy ser-
vices in Lisbon, between September 2010 and January 
2011, and between March and July 2014, and fulfilled 
the criteria above were invited to participate. Individu-
als with laboratory diagnostic of malaria at the time of 
blood collection were excluded and directed to medical 
experts for follow-up. Any other pathology that people 
might have had did not interfere with the serologic test 
used. People included were considered as potential blood 
donors. An informed consent and a signed permission to 
give 3 ml of blood for malaria studies were applied to all 
subjects at the time of enrolment. A questionnaire assess-
ing the risk of exposure was also given to all subjects 
included. This study was approved by the Ethical Council 
of the Institute of Hygiene and Tropical Medicine of Lis-
bon, Portugal.
Sample collection
Total blood was collected by venepuncture into 3 ml eth-
ylenediamine-tetraacetate (EDTA) tubes. 15  µl of total 
blood was absorbed in filter paper discs of 11 mm (What-
man, USA), allowed to dry at room temperature for 24 h 
and stored at 4 °C. The remaining sample was centrifuged 
at 4000g for 15 min, and plasma was stored at −20 °C.
Serological measurement of anti‑Plasmodium spp. 
antibodies
Total anti-Plasmodium spp. antibodies were searched in 
505 samples, by a commercial immunoenzymatic assay 
named EIA Malaria Kit Test (Bio-Rad, USA), following 
the manufacturer’s instructions. This test is used in the 
Portuguese Institute for Blood and Transplantation to 
screen potential blood donors regarding the risk of trans-
mitting malaria by blood transfusion.
The immunoassay uses four recombinant proteins 
immobilized on a solid phase where anti-Plasmodium 
spp. antibodies will bind if present in the serum/plasma 
sample. Three of the four recombinant proteins are spe-
cific to P. falciparum, with cross-reactivity for Plasmo-
dium malariae and Plasmodium ovale, and the fourth 
recombinant protein is specific for Plasmodium vivax. 
These proteins can detect total immunoglobulins (Ig) 
from class G, M and A, although not separately.
The threshold was obtained by calculating the quo-
tient of the optical density (OD; measured for each sam-
ple) and the cut-off, which is the mean of the negative 
controls for each plate plus a ponderation of 0.1 (as indi-
cated by the manufacturer). This method allowed repro-
ducible and comparable results between assays. Thus, 
samples with an OD/cut-off lower than 0.9 were consid-
ered negative while samples above 1.1 were considered 
positive. Samples with values 10% upper or 10% down 1.0 
(ranging from 0.91 to 1.09) were repeated and, when the 
value persisted, were considered inconclusive.
DNA extraction and amplification
Polimerase chain reaction (PCR) was performed to verify 
if seropositive results were due to acute infections. Plas-
modial genomic DNA was extracted from dried bloods-
pots of the seropositive samples and negative controls, 
using Chelex-100 (Bio-Rad, USA), following a protocol 
adapted from Kain and Lanar’s work [39]. Approximately 
1/4 of a 6 mm diameter filter paper with blood absorbed 
was excised, corresponding to approximately 5  µl of 
sample. Each excised filter paper was added to a 1.5 ml 
microcentrifuge tube with 300  µl 10% (w/v) Chelex-100 
and vortexed for 15  s, followed by a short spin. Tubes 
were placed in a heating block at 95 °C for 20 min. Sam-
ples were vortex for 15 s and a new short spin was made. 
The supernatant was transferred into a new 1.5 ml micro-
centrifuge tube and stored at −20  °C until required for 
DNA amplification.
PCR reactions were performed for all subjects that 
were positive in the ELISA technique. DNA of P. falci-
parum, P. vivax, P. malariae and P. ovale was amplified 
by nested-PCR, using primers that recognize the small 
subunit (18S) ribosomal RNA gene, designed by Snounou 
et  al. [40]. For amplification, the protocol was adapted 
from the manufacturer’s instructions of MyTaq Blood-
PCR Kit (Bioline, UK). Thus, for each PCR reaction were 
used 12.5 µl of MyTaq Blood-PCR Mix, 2x; 1 µl of 10 µM 
forward primer; 1  µl of 10  µM reverse primer; 1  µl of 
DNA extracted and DEPC-treated water (DNAses and 
RNAses free) (Bioline, UK) up to 25 µl.
Amplification conditions were: (a) initial denatura-
tion at 94  °C for 2:00 min; (b) denaturation at 94  °C for 
0:30 min; (c) annealing at 55 °C for 1:30 min; (d) extension 
at 72 °C for 2:00 min; repeat step (b) to (d) for 40 cycles; 
(e) final extension at 72 °C for 10:00 min. DNA extraction 
was accompanied by a negative control (a piece of blank 
filter paper) and additionally, every PCR run included a 
negative control to which no template was added.
Questionnaire
Subjects included were asked to fill in a questionnaire 
about personal characteristics such as age, country of 
birth and years of continuous residence in that country 
after birth; and travel features namely length of stay in 
endemic areas of malaria; length of time since the last 
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stay and previous history of malaria. Since epidemio-
logical studies using questionnaires are susceptible to 
errors due to recalls, the last stay in endemic areas was 
considered to be the most reliable moment from which 
there was no more risk of exposure to Plasmodium sp. 
and thus, the last possibility of having a new infection 
that may justify the antibodies detected at the time of 
this study. That variable is preferred over the last episode 
of malaria for several reasons: (1) a person may remain 
at risk of infection after the disease, every time he/she 
is in an endemic area; (2) a person may harbour para-
sites asymptomatically and (3) because the last episode 
of malaria adds more uncertainty concerning to when it 
occurred.
The “length of stay” is the duration of the last travel. 
A short stay was defined as a period of time spent in 
endemic areas of less than 6 months; and a long stay was 
considered a period of time of 6 or more months con-
tinuously spent in endemic areas. The variable “length of 
time since the last stay” refers to the time passed since 
the moment that a person leaves endemic areas until the 
moment of enrolment in this study. It was categorized 
according to the criteria for blood donation in Portugal 
(Table 1).
A pre-test of the questionnaire was made. Since tech-
nical questions were not asked, a self-administered ques-
tionnaire was applied. The questionnaire included closed, 
single‐choice questions and open questions.
Statistical analysis
Quantitative variables were described using mean and 
standard deviation (SD) or median. Data were analysed 
using descriptive statistic and hypothesis tests such as 
Chi Square test of independence, and Mann–Whitney U 
test for independent samples [41, 42]. A statistical signifi-
cance level of 5% was used to search for statistical associ-
ations or differences between the variables studied. Only 
the variables statistically significant (p  <  0.05) in bivari-
ate analysis were maintained in the second model. Multi-
variate analysis was performed in two steps: a first one 
using a univariate logistic regression and a second step 
using multiple logistic regression, based on forward like-
lihood ratio method. The quality of the adjustment of the 
model was assessed using Hosmer and Lemeshow Test. 
The hypothesis H0 was excluded when p < α (α = 0.05). 
The adjustment of the logistic regression model was also 
performed using a statistical significance level of 5%. Sta-
tistical analyses were performed with IBM SPSS Statistics 
version 20.0 software (IBM SPSS Statistics for Windows, 
Version 20.0. Armonk, NY: IBM Corp.).
Results
Characteristics of the studied population
This study included 505 individuals with previous stays 
in endemic areas of malaria, of which 336/505 were men 
(66.5%) and 169/505 were women (33.5%). The mean age 
was 41.34  years (95% confidence interval: 40.27–42.41), 
SD = 12.229, ranging from 18 to 65 years old. The median 
age was 40 years old. The most represented nationalities 
were Portugal (73.3%), followed by Angola (13.1%) and 
Mozambique (5.8%). Overall, approximately 75.8% of the 
individuals were born in a nonendemic malaria coun-
try. Table  2 summarizes the frequency of the variables 
studied.
Although 120 respondents were born in endemic areas 
of malaria, only 75 individuals lived the first 5 years of life 
in the endemic areas where they were born. Regarding 
previous episodes of the disease, “no previous history of 
malaria” was the answer for the majority of the respond-
ents (Table 2). From the individuals that answered “hav-
ing history of malaria” (165/505), only 38.6% (63/163) of 
individuals were born in endemic areas of malaria against 
to 61.3% (100/163) not born in endemic areas (Additional 
file 1).
Regarding the amount of travels to endemic areas of 
malaria, there are more people that travelled only once, 
contrarily to people who travelled more than 10 times to 
endemic areas, who accounts for the minor subpopula-
tion. For the majority of the respondents, the length of 
stay in endemic areas was less than 6 months. Relatively 
to the length of time since the last stay in endemic areas, 
there are two subpopulations that stands out: one return-
ing 4  months before their enrolment and another sub-
population that returned more than three years before 
the study (Table 2), of which 63% (113/179) had their last 
stay to endemic areas more than 10  years before their 
enrolment (Additional file 2).
Serological profile and DNA detection
The prevalence and level of total anti-Plasmodium spp. 
antibodies were determined with EIA Malaria Kit Test 
(Bio-Rad, USA). According to the serological results, 67 
individuals (13.3% of the total) were seropositive against 
Plasmodium spp. and 435 individuals (86.1%) were 
seronegative against the parasite [three results (0.6%) 
were inconclusive]. The distribution of the levels of total 
anti-Plasmodium spp. antibodies among the population 
studied (n = 505) are presented in Fig. 1a.
In order to understand how total anti-Plasmodium 
spp. antibodies are present in the population studied, we 
analysed the distribution of the levels of those antibodies 
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according to age group and the length of time since the 
last stay in endemic areas of malaria (Fig. 1b, c, respec-
tively). The variable “age” was categorized according to 
percentiles P25  =  31  years old; P50  =  40  years old and 
P75 =  51 years old. The percentage of seropositivity per 
percentile is presented in Fig.  2. The groups with more 
percentage of seropositive individuals correspond to the 
percentiles of P50 and P75, being also the subgroups with 
a higher value of OD/cut-off. Regarding the length of 
time since the last stay in endemic area, there are more 
seropositive individuals returned 4  months before their 
participation in the study and returned 3 or more years 
before their participation (Fig. 1c).
In order to distinguish between acute infections from 
old infections in seropositive subjects, and to help to 
assure that the seropositivity detected is not due to cir-
culating parasites, PCR reactions were made. Samples 
with Plasmodium DNA were excluded and thus, all sub-
jects included were negative in PCR at the time of blood 
collection.
Fig. 1 Distribution of levels of total anti‑Plasmodium spp. antibodies, according to a ELISA results: seropositive (n = 67); seronegative (n = 435) and 
inconclusive (n = 3); b distribution of levels of total anti‑Plasmodium spp. antibodies of the seropositive group, according to age groups: <31 years 
old (10/67; 14.9%); 31–40 years old (7/67; 10.4%); 40–51 years old (24/67; 35.8%); ≥51 years old (26/67; 38.8%); c Distribution of levels of total anti‑
Plasmodium spp. antibodies of the seropositive group, according to the length of time since the last stay in endemic areas of malaria: <4 months 
(34/67; 50.7%); 4 months–1 year (5/67; 7.5%); 1–3 years (4/67; 6%); ≥3 years (24/67; 35.8%)
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Statistical relation between the variables studied and total 
anti‑Plasmodium spp. antibodies
Individual and travel features that could justify the lon-
gevity of total anti-Plasmodium spp. antibodies were 
searched and statistically analysed. In the bivariate statis-
tical analysis, the presence of total antibodies anti-Plas-
modium spp. is statistically associated with the length of 
stay in endemic areas (N =  476, χ2 =  19.69, p  <  0.001) 
(Table  2). Notwithstanding, the level of total antibodies 
seems to be higher in individuals that stayed in endemic 
areas for periods of time of 6 or more months (Mann–
Whitney U = 29.90, p < 0.05) (Additional file 3).
Having been born in endemic areas may be an impor-
tant feature to influence the presence of anti-Plasmodium 
spp. antibodies (N  =  495, χ2  =  34.36, p  <  0.001), such 
as a previous history of malaria (N  =  485, χ2  =  68.50, 
p < 0.001) (Table 2).
The logistic regression model excluded some of the 
statistical significant variables calculated in the bivari-
ate analysis, indicating that only the variables “Birth in 
endemic areas” and “Previous history of malaria” were 
statistically significant, with p  =  0.011 and p  <  0.001, 
respectively (Table  2). The odds ratio of having been 
“Born in endemic areas” was 2.324 (CI95% 1209; 4464) 
comparatively to ‘Not born in endemic areas’, which 
means that having been born in an endemic area 
increases in 132.4% (2.324  −  1×100) the possibility of 
having antibodies. Notwithstanding, the odds ratio of 
having a previous history of malaria was 8.872 (CI95% 
4344; 18,118) comparatively to not have a previous his-
tory of malaria. In this case, a previous history of malaria 
increases in 878.2% the probability of an individual be 
seropositive (Table 2). The Hosmer and Lemeshow test, 
with a p value of 0.027, led to the rejection of the null 
hypothesis and to the conclusion that the model does not 
fit well the data (Additional file 4).
Regarding to the last stay in endemic areas of malaria, 
and comparing the year of the last exposure with the 
level of anti-Plasmodium spp. antibodies, two seroposi-
tive groups stand out: individuals returned in the last 
2 years and another important population returned from 
endemic areas more than 10  years before their enrol-
ment. The oldest exposures among seropositive individu-
als occurred 43  years before their participation in the 
study (Fig. 3).
Implication of anti‑Plasmodium spp. antibodies in blood 
donation
Considering that all individuals were negative in PCR and 
thus, considered as potential blood donors, the percent-
age of donors approved for blood donation was assessed, 
according to the Portuguese criteria for blood donors 
screening. Table 4 shows that if epidemiological criteria 
were applied alone to screen blood donors, there would 
be a risk of seropositive individuals be approved for 
blood donation. On the other hand, when laboratory cri-
teria were applied in combination with the epidemiologi-
cal criteria, the percentage of individuals approved was 
lower but it did not carry risk for blood donation.
Discussion
Malaria is a serious condition that still affects many peo-
ple worldwide, being a major cause of transfusion-trans-
mitted diseases [43], and Portugal remains an important 
destination for people travelling from endemic areas [38, 
44, 45]. Asymptomatic people represent an important 
risk to malaria transmitted through blood transfusion 
[46, 47]. The existence of anti-Plasmodium spp. anti-
bodies in a blood unit may represent a risk of malaria 
transmission, since it is not clear what their presence 
means in the context of blood transfusion. As a result, 
Fig. 2 Percentage of seropositive individuals according to the pres‑
ence of total antibodies anti‑Plasmodium spp. in each percentile. 
Variable “Age” categorized according to P25, P50 and P75, resulting in 
four age groups: <31 years old (10/67; 14.9%); 31–40 years old (7/67; 
10.4%); 40–51 years old (24/67; 35.8%); ≥51 years old (26/67; 38.8%)
Fig. 3 Distribution of antibody levels among the seropositive group, 
according to the year of their last stay in endemic areas of malaria
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all seropositive individuals for malaria are excluded from 
blood donations.
The longevity of those antibodies is also not well deter-
mined, with several studies indicating different half-life 
of antibodies anti-Plasmodium spp. [5, 6]. Therefore, the 
effect of malaria exposures in the blood donation context 
was analysed, treating the subjects included as potential 
blood donors and thus, applying the Portuguese criteria 
for donor eligibility. Characteristics that could justify the 
longevity of the antibodies detected were also searched.
A group of 505 people, ranging from 18 to 65  years 
old, with previous stays in endemic areas of malaria were 
included. The majority of the individuals were born in 
Portugal (a nonendemic area), and thus its immune sys-
tem was not stimulated against Plasmodium antigens 
during childhood. Negative results from PCR indicate 
that none of the serological reactivity detected were due 
to acute infections at the time of enrolment. Overall, 
13.3% of the individuals were seropositive for antibodies 
anti-Plasmodium spp. Statistical analysis were performed 
to search for associations between the presence of total 
anti-Plasmodium spp. antibodies and some personal and 
travels characteristics (age; country of birth; number of 
travels to endemic areas; the length of stay in endemic 
areas and the length of time since the last stay). Results 
are summarized in Tables 2 and 3.
The effect of age is not completely understood. 
Although some studies suggest that a protective immune 
response is acquired and developed early in life, others 
indicate that a more mature immune system develops a 
specific immune response more efficiently [48–50]. The 
results obtained in the present study suggest that the 
presence of total anti-Plasmodium spp. antibodies is not 
related to the age of subjects, being a confounding vari-
able of the studied population. However, analysing the 
percentiles of the variable “age” it is possible to notice 
that there are more seropositive subjects in the two older 
percentiles (Fig. 2). The only study founded enrolling an 
adult population showed a high prevalence of antibodies 
against P. vivax between the ages of 25–50 years [51]. The 
results reported in the present study indicate that there 
are more percentage of individuals with total antibodies 
against Plasmodium spp. from 40 to 65  years old than 
among younger individuals, aged from 18 to 40  years 
(Fig. 2).
To be born in endemic areas seems to be an important 
feature that may justify the presence of anti-Plasmo-
dium spp. antibodies (OR  =  2.324 [CI95% 1209; 4464]). 
Although it has been described that children under 
5  years old are one of the most vulnerable groups to 
malaria infections [52], the present report suggests that 
living the first 5 years of life in those areas does not seem 
to be related to the persistence of total anti-Plasmodium 
spp. antibodies until adulthood. Mackinstosh and col-
leagues analysed the blood of 272 children under 10 years 
old and indicated the presence of anti-Plasmodium falci-
parum antibodies only in parasitized children, suggesting 
that those antibodies may be short-lived [53]. To be true 
that age per se is not a factor that stimulates antibodies 
that can persist for long periods of time, these results 
may raise a question about the applicability of some crite-
ria in blood donations.
According to the statistical results obtained in this 
study, the presence of total antibodies is related to a pre-
vious history of malaria (N = 485, χ2 = 68.50, p < 0.001), 
(OR = 8.872 [CI95% 4344; 18,118]), although it does not 
take into account the moment when it occurred. Those 
results are consonant with a study of Nguyen including 
blood donors in the USA, in which the authors analysed 
the risk of transfusion-transmitted malaria between a 
group of deferred donors and a group of accepted blood 
donors [54]. That study suggests that there is a signifi-
cant risk of transmitting malaria through blood trans-
fusion when people with past episodes of malaria are 
accepted for donation (without serologic testing) [54]. 
Although the presence of total anti-Plasmodium spp. 
antibodies seemed to be also dependent of the length of 
stay in endemic areas (N =  476, X2 =  19.69, p < 0.001) 
according to bivariate analysis, the logistic regression 
model indicated that this is another confounding vari-
able. Regarding other variables studied, as the number 
of travels to endemic areas and the time passed since the 
last stay in endemic areas (as well as the first 5 years of 
life in endemic areas, already mentioned above), statisti-
cal analysis indicate that serological results are independ-
ent of those variables, showing no differences statistically 
significant.
The logistic regression model excluded some of the 
variables that were statistical significant on the bivari-
ate analysis, indicating that only the variables “birth in 
Table 3 Statistical relation between variable “age” and serological results






Mean rank p value
Age (n = 502) Group of seropositive (n = 67) 46 46.13 ± 1.46 10.69 309.40 <0.001
Group of seronegative (n = 435) 39 40.59 ± 0.58 242.58
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endemic areas” and “previous history of malaria” are 
statistically significant. Therefore, the variables “length 
of stay” and “age” are possible confounding variables. 
Although model’s coefficients were statistically signifi-
cant, Hosmer and Lemeshow test indicated that there 
was no good quality of model’s adjustment, which can be 
explained by the existence of other features not included 
in this study that could better explain the presence and 
longevity of total anti-Plasmodium spp. antibodies.
Although statistical analysis does not give a significant 
meaning when serological results are analysed regard-
ing the length of time since the last stay (Table  2), the 
analyses of Fig. 3 shows two important populations that 
shall be highlighted: one corresponds to individuals who 
returned from endemic areas within 2  years before the 
study, and another population showing serological reac-
tivity 40–50  years after the last stay in endemic areas. 
The two oldest exposures correspond to two people with 
stays in African countries: one Portuguese man that trav-
elled to Guinea-Bissau for military duties, reported pre-
vious episodes of malaria and returned in 1971, with no 
more stays in endemic areas since. The second person, 
also a man, was born in Mozambique and lived there 
for 4  years, between 1967 and 1971, returning 43  years 
before the study execution, not having history of malaria 
episodes. The literature is ambiguous about the longevity 
of anti-Plasmodium spp. antibodies, but it can be found 
that the humoral immune response against Plasmodium 
spp. may be transient, remaining up to 3–5  years with-
out re-exposures [55]. A study of Fowkes et al. including a 
population of pregnant women in northwestern Thailand, 
estimated a half-life of 7.6  years for antibodies against 
PfAMA1 of P. falciparum in infected women, although 
for uninfected participants the longest persistence time 
calculated was only 3.1 years for MSP2 of P. falciparum 
[5]. Faddy et al. investigated the longevity of antibodies in 
a population of blood donors in a nonendemic area and 
indicated a median seroreversion time of 19.6  months. 
Also, the authors estimated that 20% of people with stays 
in endemic area of less than 6 months would serorevert 
3 years after the initial reactive result, and 2% of the peo-
ple with stays in endemic areas of more than six months 
would test seronegative in 5 years [6]. A study of Druilhe 
et al. reported the presence of antibodies against P. falci-
parum sporozoites in African adults up to 11 years after 
the last exposure [56]. Therefore, the persistence of anti-
bodies detected in the present report is significantly 
longer than previously described [5, 6, 56].
The implication of the antibodies detected for blood 
donation was determined only for two of the four Por-
tuguese blood donation criteria due to its inapplicabil-
ity: the condition “Individuals with previous episodes of 
malaria” uses epidemiological and laboratory criteria that 
are dependent, not allowing a person to donate blood if 
one of the criteria is not verified, and thus our analyse 
could not be done. The condition “Individuals with febrile 
episodes undiagnosed during or 6  months after a travel 
for endemic areas” cannot be analysed in this study, since 
the database did not include symptomatic individuals.
As shown in Table  4, epidemiological criteria (which 
only rely in the length of time since the last stay in 
endemic areas) approve a higher percentage of potential 
blood donors than laboratory criteria. However, it carries 
a risk for blood safety since epidemiological criteria alone 
would allow the donation of blood from individuals that 
are seropositive for malaria. Moreover, laboratory crite-
ria are more selective and the percentage of approval is 
significantly lower. It seems that epidemiological criteria 
used alone are insufficient to guarantee the blood safety 
and that laboratory criteria are more reliable once all the 
individuals approved would be seronegative, and thus the 
uncertainty about blood safety decreases.
Despite all efforts made to obtain accurate answers 
from epidemiological questionnaires, these kind of 
Table 4 Percentage of donors approved according to the Portuguese criteria for blood screening and serologic results
Condition Criteria for approval Donors approval %
Individuals who lived the first 
5 years of life in endemic areas 
(n = 85)
Epidemiological criterion 3 year after return (n = 45) 52.9 (45/85) Of which 28.9% (13/45) that 
would be approved were 
seropositive
Laboratory criterion If returned between 4 month 
and 3 year and seronegative 
(n = 14)
16.5 (14/85) (All approved would be 
seronegative)
Asymptomatic travellers (length 
of stay <6 months) from 
endemic areas (n = 308)
Epidemiological criterion 1 year after return (n = 147) 47.7 (147/308) Of which 5.4% (8/147) that 
would be approved were 
seropositive
Laboratory criterion If returned between 4 month 
and 1 year with serological test 
nonreactive (n = 31)
10.1 (31/308) (All approved would be 
seronegative)
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studies are susceptible to recall bias, which is important 
to consider when analysing the results.
Serological assays used as screening methods do 
not necessarily indicate that a person is infected at the 
moment of the donation, but it constitutes an important 
indicator to measure the risk of transmitting this infec-
tious disease. In the USA, where the screening of blood 
donors relies only in epidemiological questionnaires and 
periods of suspension, it was described a case of transfu-
sion-transmitted malaria caused by P. malariae 44 years 
after exposure in an endemic area of malaria [57]. The 
present study intends to alert for similar cases, since it 
was detected anti-Plasmodium spp. antibodies many 
years after exposure and the risk for blood transfusion 
is not known yet. Thus, measures of eligibility of blood 
donors should be reinforced. Complementary measures 
to ensure the safety of the blood may include policies that 
demand blood screening in areas where those policies 
do not exist yet, and that blood screening at a laboratory 
level becomes a regular procedure in every blood dona-
tion. Other studies have suggested that the screening of 
blood donors should include the antigen detection with 
monoclonal antibodies or the detection of its nucleic 
acids, in order to reinforce the performance of serologic 
tests and improve the screening methods and, conse-
quently, improve blood safety [58, 59].
New studies should be performed to deeply investigate 
molecular characteristics and immunological effects of 
those antibodies detected decades after exposure. Other 
subjects or travel characteristics should be considered 
to contribute to the longevity of anti-Plasmodium spp. 
antibodies. The implication of those antibodies on the 
criteria of donors eligibility (including the two other 
requirements for blood donation not contemplated in 
the present work) should also be assessed in broader and 
representative populations.
Conclusions
In the present study, an important percentage of indi-
viduals returned from endemic areas more than 10 years 
before their enrolment was detected with total anti-Plas-
modium spp. antibodies circulating in their bloodstream.
Some factors that may influence the longevity of total 
anti-Plasmodium spp. antibodies over time were identi-
fied: (a) had been born in endemic areas and (b) previous 
history of malaria. On the other hand, living in endemic 
areas during childhood does not seem to be related to 
the longevity of total anti-Plasmodium spp. antibodies, 
as well as the number of travels to endemic areas or the 
length of time spent in endemic areas, for the popula-
tion studied. Although the length of time since the last 
stay in endemic areas was not statistically significant, the 
presence of total anti-Plasmodium spp. antibodies in the 
bloodstream of individuals many years after exposure, 
with no history of malaria in the meantime, is important 
to highlight.
In the blood donation context, epidemiological ques-
tionnaires should be reinforced with serological tests to 
guarantee the safety and quality of the blood donated. 
New studies should be performed to understand the bio-
logical nature of those long-lived immunoglobulins, their 
specific role in the immunity of malaria and their impli-
cation in blood transfusion.
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